Total Payments
$8,899
2024 Payments
$2,928
Companies
54
Transactions
438
Medicare Patients
16,954
Medicare Billing
$2.1M
Payment Breakdown by Category
Food & Beverage$7,008 (78.8%)
Travel$1,650 (18.5%)
Education$240.69 (2.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,008 | 428 | 78.8% |
| Travel and Lodging | $1,650 | 6 | 18.5% |
| Education | $240.69 | 4 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $1,615 | 9 | $0 (2024) |
| Abbott Laboratories | $835.98 | 29 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $562.20 | 43 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $490.56 | 60 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $480.57 | 30 | $0 (2022) |
| Amgen Inc. | $475.03 | 31 | $0 (2024) |
| iRhythm Technologies, Inc. | $385.30 | 16 | $0 (2024) |
| Boston Scientific Corporation | $383.36 | 21 | $0 (2024) |
| PFIZER INC. | $380.25 | 26 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $357.53 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,928 | 104 | Janssen Research & Development, LLC ($1,615) |
| 2023 | $771.81 | 57 | Novartis Pharmaceuticals Corporation ($175.83) |
| 2022 | $926.29 | 65 | Amgen Inc. ($129.52) |
| 2021 | $899.99 | 59 | Janssen Pharmaceuticals, Inc ($160.39) |
| 2020 | $1,009 | 43 | iRhythm Technologies, Inc. ($186.69) |
| 2019 | $1,053 | 44 | GE HEALTHCARE ($194.81) |
| 2018 | $622.88 | 34 | Abbott Laboratories ($221.47) |
| 2017 | $688.10 | 32 | BOSTON SCIENTIFIC CORPORATION ($130.30) |
All Payment Transactions
438 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | CARDIVA MEDICAL, INC. | CARDIVA VASCADE 6/7F VCS (Device) | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: DEVICES | ||||||
| 12/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Obesity | ||||||
| 12/12/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $12.81 | General |
| Category: Cardiovascular | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $3.75 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Cardiology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $5.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/05/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Obesity | ||||||
| 10/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $10.81 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/18/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $47.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/18/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/17/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $15.70 | General |
| Category: Heart Failure and Hypertension | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.81 | General |
| Category: Cardiovascular | ||||||
| 10/10/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $5.16 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/08/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $13.90 | General |
| Category: Cardiology | ||||||
| 09/28/2024 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: Heart Failure | ||||||
| 09/26/2024 | Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $32.97 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $8.77 | General |
| Category: Cardiovascular | ||||||
| 09/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Diabetes | ||||||
| 09/10/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $4.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: DIABETES | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $1.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 3,987 | 5,786 | $1.4M | $532,092 |
| 2022 | 22 | 4,274 | 6,288 | $1.5M | $557,312 |
| 2021 | 19 | 4,376 | 6,426 | $1.4M | $537,563 |
| 2020 | 19 | 4,317 | 6,285 | $1.3M | $473,595 |
Total Patients
16,954
Total Services
24,785
Medicare Billing
$2.1M
Procedure Codes
90
All Medicare Procedures & Services
90 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 825 | 1,226 | $283,206 | $118,780 | 41.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 242 | 244 | $264,252 | $94,717 | 35.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 294 | 605 | $133,100 | $59,941 | 45.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 237 | 238 | $120,666 | $37,726 | 31.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 223 | 253 | $108,790 | $35,897 | 33.0% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 244 | 252 | $53,995 | $35,875 | 66.4% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 44 | 45 | $67,815 | $33,818 | 49.9% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 182 | 736 | $78,016 | $32,040 | 41.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 55 | 128 | $74,752 | $22,600 | 30.2% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 273 | 284 | $46,860 | $14,981 | 32.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 834 | 1,172 | $43,364 | $12,757 | 29.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 69 | 69 | $30,498 | $11,892 | 39.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 43 | 54 | $16,686 | $6,491 | 38.9% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 27 | 28 | $29,752 | $5,361 | 18.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $7,514 | $2,471 | 32.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 30 | 30 | $15,210 | $1,709 | 11.2% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 50 | 50 | $4,500 | $1,638 | 36.4% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 47 | 48 | $2,688 | $993.67 | 37.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 127 | 140 | $4,200 | $897.75 | 21.4% |
| 93042 | Electrocardiogram (ecg) 1 to 3 leads with review by physician only | Facility | 2023 | 58 | 101 | $1,515 | $569.64 | 37.6% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 30 | 30 | $1,050 | $547.40 | 52.1% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 36 | 36 | $900.00 | $388.44 | 43.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 785 | 1,234 | $285,054 | $124,277 | 43.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 273 | 274 | $296,742 | $114,483 | 38.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 263 | 591 | $130,020 | $51,520 | 39.6% |
About Dr. Ali Moosvi, M.D
Dr. Ali Moosvi, M.D is a Cardiovascular Disease healthcare provider based in Brick, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1093796948.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ali Moosvi, M.D has received a total of $8,899 in payments from pharmaceutical and medical device companies, with $2,928 received in 2024. These payments were reported across 438 transactions from 54 companies. The most common payment nature is "Food and Beverage" ($7,008).
As a Medicare-enrolled provider, Moosvi has provided services to 16,954 Medicare beneficiaries, totaling 24,785 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 90 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Brick, NJ
- Active Since 11/08/2005
- Last Updated 02/29/2008
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1093796948
Products in Payments
- XARELTO (Drug) $562.20
- ELIQUIS (Drug) $544.70
- Repatha (Biological) $446.29
- BRILINTA (Drug) $408.41
- ZIO Patch (Device) $278.43
- ENTRESTO (Drug) $271.03
- Vascepa (Drug) $245.52
- LEQVIO (Drug) $219.53
- Artis pheno (Device) $180.15
- Impella (Device) $150.84
- VERQUVO (Drug) $144.37
- HMG-CoA reductase inhibitor. (Drug) $138.08
- PRADAXA (Drug) $131.84
- CAMZYOS (Drug) $130.90
- General - Therapies (Device) $123.60
- Quadra Assura CRT Defibrillator (Device) $112.12
- (5044) MCOT (Device) $110.86
- Confirm Rx (Device) $110.08
- ZIO XT Patch (Device) $106.87
- FARXIGA (Drug) $99.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Brick
Dr. Todd Cohen, D.o, D.O
Cardiovascular Disease — Payments: $20,455
Cardiovascular Disease $20,455
Dr. Michael Devita, D.o, D.O
Cardiovascular Disease — Payments: $19,036
Cardiovascular Disease $19,036
Roy Sauberman, M.d, M.D
Cardiovascular Disease — Payments: $14,304
Cardiovascular Disease $14,304
Harshil Patel, M.d, M.D
Cardiovascular Disease — Payments: $5,705
Cardiovascular Disease $5,705
Hojun Yoo, M.d, M.D
Cardiovascular Disease — Payments: $4,103
Cardiovascular Disease $4,103
Sagar Patel, D.o, D.O
Cardiovascular Disease — Payments: $3,872
Cardiovascular Disease $3,872